You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 8,524,880


✉ Email this page to a colleague

« Back to Dashboard


Title:Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.
Inventor(s): Wilton; Stephen Donald (Applecross, AU), Fletcher; Sue (Bayswater, AU), McClorey; Graham (Bayswater, AU)
Assignee: The University of Western Australia (Crawley,, AU)
Filing Date:Jul 15, 2010
Application Number:12/837,356
Claims:1. An isolated antisense oligonucleotide of 20 to 50 nucleotides in length comprising at least 17 consecutive nucleotides of SEQ ID NO: 207, wherein the oligonucleotide specifically hybridizes to an exon 45 acceptor splice site of a human dystrophin gene, inducing exon 45 skipping, and wherein the uracil bases are optionally thymine bases.

2. The antisense oligonucleotide of claim 1, wherein the uracil bases are thymine bases.

3. The antisense oligonucleotide of claim 1 comprising SEQ ID NO: 207.

4. The antisense oligonucleotide of claim 1 consisting of SEQ ID NO: 207.

5. The antisense oligonucleotide of claim 1 comprising SEQ ID NO: 207, wherein the uracil bases are thymine bases.

6. The antisense oligonucleotide of claim 1 comprising 25 nucleotides in length.

7. The antisense oligonucleotide of claim 1 comprising 17-30 nucleotides in length.

8. The antisense oligonucleotide of claim 1 comprising 20-31 nucleotides in length.

9. The antisense oligonucleotide of claim 1, wherein the oligonucleotide does not activate RNase H.

10. The antisense oligonucleotide of claim 1, comprising a non-natural backbone.

11. The antisense oligonucleotide of claim 10, wherein the sugar moieties of the oligonucleotide backbone are replaced with non-natural moieties.

12. The antisense oligonucleotide of claim 11, wherein the non-natural moieties are morpholinos.

13. The antisense oligonucleotide of claim 1, wherein the inter-nucleotide linkages of the oligonucleotide backbone are replaced with non-natural inter-nucleotide linkages.

14. The antisense oligonucleotide of claim 13, wherein the non-natural inter-nucleotide linkages are modified phosphates.

15. The antisense oligonucleotide of claim 1, wherein the sugar moieties of the oligonucleotide backbone are replaced with non-natural moieties and the inter-nucleotide linkages of the oligonucleotide backbone are replaced with non-natural inter-nucleotide linkages.

16. The antisense oligonucleotide of claim 15, wherein the non-natural moieties are morpholinos and the non-natural internucleotide linkages are modified phosphates.

17. The antisense oligonucleotide of claim 16, wherein the modified phosphates are methyl phosphonates, methyl phosphorothioates, phosphoromorpholidates, phosphoropiperazidates or phosphoroamidates.

18. The antisense oligonucleotide of claim 1, wherein the oligonucleotide is a 2'-O-methyl-oligoribonucleotide.

19. The antisense oligonucleotide of claim 1, wherein the oligonucleotide is a peptide nucleic acid.

20. The antisense oligonucleotide of claim 1, wherein the oligonucleotide is chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide.

21. The antisense oligonucleotide of claim 20, wherein the oligonucleotide is conjugated to a polyamine.

22. The antisense oligonucleotide of claim 20, wherein the oligonucleotide is chemically linked to a polyethylene glycol chain.

23. An isolated antisense oligonucleotide of 20 to 50 nucleotides in length comprising at least 17 consecutive nucleotides complementary to an exon 45 target region of a human dystrophin gene designated as annealing site H45A(-06+20), wherein the antisense oligonucleotide specifically hybridizes to the acceptor splice site inducing exon 45 skipping, and wherein uracil bases in the antisense oligonucleotide are optionally thymine bases.

24. The antisense oligonucleotide of claim 23, wherein the uracil bases are thymine bases.

25. The antisense oligonucleotide of claim 23 comprising 25 nucleotides in length.

26. The antisense oligonucleotide of claim 23 comprising 17-30 nucleotides in length.

27. The antisense oligonucleotide of claim 23 comprising 20-31 nucleotides in length.

28. The antisense oligonucleotide of claim 23 comprising at least 17 consecutive nucleotides 100% complementary to the exon 45 target region.

29. The antisense oligonucleotide of claim 23 comprising 20-31 nucleotides in length and at least 17 consecutive nucleotides 100% complementary to the exon 45 target region.

30. The antisense oligonucleotide of claim 23 comprising at least 20 consecutive nucleotides complementary to the exon 45 target region.

31. The antisense oligonucleotide of claim 23 comprising at least 20 consecutive nucleotides 100% complementary to the exon 45 target region.

32. The antisense oligonucleotide of claim 23 comprising 20-31 nucleotides in length and at least 20 consecutive nucleotides complementary to the exon 45 target region.

33. The antisense oligonucleotide of claim 23, wherein the oligonucleotide does not activate RNase H.

34. The antisense oligonucleotide of claim 23, comprising a non-natural backbone.

35. The antisense oligonucleotide of claim 34, wherein the sugar moieties of the oligonucleotide backbone are replaced with non-natural moieties.

36. The antisense oligonucleotide of claim 35, wherein the non-natural moieties are morpholinos.

37. The antisense oligonucleotide of claim 23, wherein the inter-nucleotide linkages of the oligonucleotide backbone are replaced with non-natural inter-nucleotide linkages.

38. The antisense oligonucleotide of claim 37, wherein the non-natural inter-nucleotide linkages are modified phosphates.

39. The antisense oligonucleotide of claim 23, wherein the sugar moieties of the oligonucleotide backbone are replaced with non-natural moieties and the inter-nucleotide linkages of the oligonucleotide backbone are replaced with non-natural inter-nucleotide linkages.

40. The antisense oligonucleotide of claim 39, wherein the non-natural moieties are morpholinos and the non-natural internucleotide linkages are modified phosphates.

41. The antisense oligonucleotide of claim 40, wherein the modified phosphates are methyl phosphonates, methyl phosphorothioates, phosphoromorpholidates, phosphoropiperazidates or phosphoroamidates.

42. The antisense oligonucleotide of claim 23, wherein the oligonucleotide is a 2'-O-methyl-oligoribonucleotide.

43. The antisense oligonucleotide of claim 23, wherein the oligonucleotide is a peptide nucleic acid.

44. The antisense oligonucleotide of claim 23, wherein the oligonucleotide is chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide.

45. The antisense oligonucleotide of claim 44, wherein the oligonucleotide is conjugated to a polyamine.

46. The antisense oligonucleotide of claim 44, wherein the oligonucleotide is chemically linked to a polyethylene glycol chain.

47. An isolated antisense oligonucleotide of 20 to 50 nucleotides in length comprising at least 20 consecutive nucleotides of SEQ ID NO: 207, wherein the uracil bases are optionally thymine bases.

48. The antisense oligonucleotide of claim 47, wherein the uracil bases are thymine bases.

49. The antisense oligonucleotide of claim 47 comprising 25 nucleotides in length.

50. The antisense oligonucleotide of claim 47 comprising 20-31 nucleotides in length.

51. The antisense oligonucleotide of claim 47, wherein the oligonucleotide does not activate RNase H.

52. The antisense oligonucleotide of claim 47, comprising a non-natural backbone.

53. The antisense oligonucleotide of claim 52, wherein the sugar moieties of the oligonucleotide backbone are replaced with non-natural moieties.

54. The antisense oligonucleotide of claim 53, wherein the non-natural moieties are morpholinos.

55. The antisense oligonucleotide of claim 47, wherein the inter-nucleotide linkages of the oligonucleotide backbone are replaced with non-natural inter-nucleotide linkages.

56. The antisense oligonucleotide of claim 55, wherein the non-natural inter-nucleotide linkages are modified phosphates.

57. The antisense oligonucleotide of claim 47, wherein the sugar moieties of the oligonucleotide backbone are replaced with non-natural moieties and the inter-nucleotide linkages of the oligonucleotide backbone are replaced with non-natural inter-nucleotide linkages.

58. The antisense oligonucleotide of claim 57, wherein the non-natural moieties are morpholinos and the non-natural internucleotide linkages are modified phosphates.

59. The antisense oligonucleotide of claim 58, wherein the modified phosphates are methyl phosphonates, methyl phosphorothioates, phosphoromorpholidates, phosphoropiperazidates or phosphoroamidates.

60. The antisense oligonucleotide of claim 47, wherein the oligonucleotide is a 2'-O-methyl-oligoribonucleotide.

61. The antisense oligonucleotide of claim 47, wherein the oligonucleotide is a peptide nucleic acid.

62. The antisense oligonucleotide of claim 47, wherein the oligonucleotide is chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide.

63. The antisense oligonucleotide of claim 62, wherein the oligonucleotide is conjugated to a polyamine.

64. The antisense oligonucleotide of claim 62, wherein the oligonucleotide is chemically linked to a polyethylene glycol chain.

65. A pharmaceutical composition comprising an antisense oligonucleotide of claim 1, and a pharmaceutically acceptable carrier.

66. A pharmaceutical composition comprising an antisense oligonucleotide of claim 23, and a pharmaceutically acceptable carrier.

67. A pharmaceutical composition comprising an antisense oligonucleotide of claim 47, and a pharmaceutically acceptable carrier.

68. A method of inducing exon-skipping of dystrophin exon 45, comprising administering a pharmaceutical composition of claim 65.

69. A method of treating Duchenne muscular dystrophy, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition of claim 65.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.